2-(1,2,3,4-tetrahydroquinolin-2-yl)-1H-benzo[d]imidazole-4-carboxamide | 1260502-45-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(1,2,3,4-tetrahydroquinolin-2-yl)-1H-benzo[d]imidazole-4-carboxamide
• 英文别名: 2-(1,2,3,4-tetrahydroquinolin-2-yl)-1H-benzimidazole-4-carboxamide
• CAS: 1260502-45-1
• 化学式: C₁₇H₁₆N₄O
• 分子量: 292.34
• InChiKey: QRZCBVRDIYSPKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  83.8
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  tert-butyl 2-(4-carbamoyl-1H-benzo[d]imidazol-2-yl)-3,4-dihydroquinoline-1(2H)-carboxylate 在 盐酸 、 碳酸氢钠 作用下， 以 甲醇 、 水 为溶剂， 生成 2-(1,2,3,4-tetrahydroquinolin-2-yl)-1H-benzo[d]imidazole-4-carboxamide
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF PARP ACTIVITY
  [FR] INHIBITEURS À PETITE MOLÉCULE DE L'ACTIVITÉ DE PARP

  摘要：

  公开号：

  WO2011002520A3

文献信息

• SMALL MOLECULE INHIBITORS OF PARP ACTIVITY
  申请人：Panicker Bijoy

  公开号：US20120184533A1

  公开（公告）日：2012-07-19

  Compounds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer.

  提供了抑制聚腺苷酸核糖合酶（PARP）活性的化合物和制药组合物。这些化合物在治疗各种疾病、状况和损伤方面具有用处，如中风、心肌梗死、各种器官的缺血再灌注损伤、创伤性脑损伤、动脉粥样硬化、炎症性疾病和癌症。
• Small molecule inhibitors of PARP activity
  申请人：Panicker Bijoy

  公开号：US08513433B2

  公开（公告）日：2013-08-20

  Compounds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such compounds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer.

  提供抑制多聚腺苷酸核糖合酶（PARP）活性的化合物和药物组合物。这些化合物在治疗各种疾病、状况和损伤方面非常有用，例如中风、心肌梗死、各种器官的缺血再灌注损伤、创伤性脑损伤、动脉粥样硬化、炎症性疾病和癌症。
• SERUM AND TISSUE BIOMARKERS OF HUMAN HCC
  申请人：Modpro AB

  公开号：EP2553458A2

  公开（公告）日：2013-02-06
• BIOMARKER COMPOSITION FOR DETECTING DIABETIC RETINOPATHY AND DIAGNOSTIC KIT THEREFOR
  申请人：KIM Young-Soo

  公开号：US20120183973A1

  公开（公告）日：2012-07-19

  Provided is a biomarker composition for detecting diabetic retinopathy, comprising at least one protein selected from the group consisting of proteins as set forth in SEQ ID NOS: 1 to 169, a method and a kit for diagnosing diabetic retinopathy using the same. The biomarker can provide fundamental information in researching vitreoretinal disorders, such as, diabetic retinopathy and the protein may be used in a method and a kit for diagnosing diabetic retinopathy with a molecule specifically binding thereto.
• BIOMARKERS FOR LYMPHOMA
  申请人：BATTELLE MEMORIAL INSTITUTE

  公开号：US20130137595A1

  公开（公告）日：2013-05-30

  A biomarker, method, test kit, and diagnostic system for detecting the presence of lymphoma in a person are disclosed. The lymphoma may be Hodgkin's lymphoma or non-Hodgkin's lymphoma. The person may be a high-risk subject. In one embodiment, a plasma sample from a person is obtained. The level of at least one protein listed in Table S3 in the plasma sample is measured. The level of at least one protein in the plasma sample is compared with the level in a normal or healthy subject. The lymphoma is diagnosed based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level.